Publications

5674 Results

Efficacy of low dose involved field (LDIF) XRT in producing and maintaining CR following PR induction with MOP-BAP chemotherapy in hodgkin's disease, results of Southwest Oncology Group study 7808

Authors
C Fabian;S Dahlberg;T Miller;S Jones;P Grozea;F Morrison;C Mansfield
Journal / Conference
ASCO 8:253(#987)
Year
1989
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-7808

Adjuvant chemotherapy for poor prognosis estrogen receptor negative stage II-III breast cancer; a comparison of one year vs two years CMFVP.

Authors
S Green;S Rivkin;B Metch;CK Osborne;A Cruz;S Balcerzak;R Stevens;J Costanzi
Journal / Conference
ASCO 8:24(#88)
Year
1989
Research Committee(s)
Breast
Study Number(s)
SWOG-7827

A stratified, randomized trial of busulfan (B) or busulfan plus vitamin A (BVA) for the management of chronic myelogenous leukemia(CML).

Authors
FL Meyskens Jr;K Kopecky;M Grever
Journal / Conference
ASCO 8:203(#790)
Year
1989
Research Committee(s)
Leukemia
Study Number(s)
SWOG-7984

A randomized trial of cisplatin (P), vinblastine (VLB) plus either bleomycin (PVB), or VP-16 (VPV) in patients with advanced testicular cancer.

Authors
MK Samson;ED Crawford;S Altman;R Natale;NT Shah;B Blumenstein
Journal / Conference
ASCO 8:134(#522)
Year
1989
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8110

BCG versus adriamycin intravesical therapy for in situ and papillary transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group study

Authors
DL Lamm;J Crissman;ED Crawford;B Blumenstein;JE Montie;PT Scardino;HB Grossman;T Stanisic;JA Smith;M Sarosdy
Journal / Conference
ASCO 8:130(504)
Year
1989
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8216/38

Combination chemotherapy is superior to hemibody irradiation(HXRT) for remission consolidation in multiple myeloma (MM): A Southwest Oncology Group (SWOG) study.

Authors
S Salmon;D Tesh;J Crowley;S Saeed;P Finley;D Stock-Novack
Journal / Conference
ASCO 8:250(#975)
Year
1989
Research Committee(s)
Myeloma
Study Number(s)
SWOG-8229/30

Phase II trial of cisplatin (CP) and 5-fluorouracil (5FU) with or without allopurinol (ALL) for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: A Southwest Oncology Group study.

Authors
GR Weiss;S Green;D Stock-Novack;DS Alberts;R Giudice
Journal / Conference
ASCO 8:158(#616)
Year
1989
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-8321

Evaluation of fludarabine phosphate (FLAMP) in patients with advanced mycosis fungoides (MF). A Southwest Oncology Group study.

Authors
D Von Hoff;S Dahlberg;R. Hartsock
Journal / Conference
ASCO 8:269(#1050)
Year
1989
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8323

Increased risk of early death (ED) with high dose ara-C (HDAC)and m-AMSA compared to HDAC alone or HDAC and mitoxantrone (MITOX) inhigh risk nonlymphocytic leukemia (ANL)

Authors
C Karanes;KJ Kopecky;BGM Durie;MR Grever
Journal / Conference
ASCO 8:201(#783)
Year
1989
Research Committee(s)
Leukemia
Study Number(s)
SWOG-8326/27

5-fluorouracil (5FU) and folinic acid (FA): for the treatment ofmetastatic gastric cancer.

Authors
JL Berenberg;PJ Goodman;N Oishi;T Fleming;RB Natale;LH Hutchins;GT Guy;J Macdonald
Journal / Conference
ASCO 8:101(#392)
Year
1989
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-8390